Lv720
3230 积分 2025-10-14 加入
Canagliflozin improves fatty acid oxidation and ferroptosis of renal tubular epithelial cells via FOXA1-CPT1A axis in diabetic kidney disease
1个月前
已完结
Dapagliflozin Alleviates Diabetic Kidney Disease via Hypoxia Inducible Factor 1α/Heme Oxygenase 1-Mediated Ferroptosis
1个月前
已完结
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
1个月前
已完结
Therapeutic Targets for Diabetic Kidney Disease: Proteome-Wide Mendelian Randomization and Colocalization Analyses
1个月前
已完结
Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine
1个月前
已完结
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
1个月前
已完结
Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China
1个月前
已完结
Efficacy and safety of HRS-7535, an oral small-molecule GLP-1 receptor agonist, in patients with diabetic kidney disease (SOLID-DKD): a randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Effect of the glucagon-like peptide-1 receptor agonists dulaglutide on kidney outcomes in db/db mice
1个月前
已完结
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials
1个月前
已完结